Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks. We thought to assess the effects of Tesamorelin, a synthetic growth hormon...
Badran AS, Helal A, Shata KS et al. — Obesity research & clinical practice
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1). ...
Ellis RJ, Vaida F, Hu K et al. — The Journal of infectious diseases
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiret...
Russo SC, Ockene MW, Arpante AK et al. — AIDS (London, England)
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III...
Rahman F, McLaughlin T, Mesquita P et al. — Journal of clinical and translational science
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity among people living with HIV that has a more aggressive course than NAFLD among the general population. In a recent randomized placebo-controlled trial, we demonstrated that the grow...
Fourman LT, Billingsley JM, Agyapong G et al. — JCI insight
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Non-alcoholic fatty liver disease (NAFLD) is a substantial cause of comorbidity in people with HIV and there are no proven pharmacological treatments for the disease in this population. We assessed the effects of tesamorelin on liver fat and histo...
Stanley TL, Fourman LT, Feldpausch MN et al. — The lancet. HIV
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects
Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and pulsatile growth hormone (GH) secretion and subsequently increases insulin-like growth factor (IGF)-1. Limited information is available about t...
González-Sales M, Barrière O, Tremblay PO et al. — Clinical pharmacokinetics
Spotlight on tesamorelin in HIV-associated lipodystrophy
Tesamorelin (Egrifta™) is a synthetic analog of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. It is the first and, so far, only...
Dhillon S — BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Tesamorelin
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodyst...
Grunfeld C, Dritselis A, Kirkpatrick P — Nature reviews. Drug discovery
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor
Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and...
Tomlinson B — Current opinion in investigational drugs (London, England : 2000)